Abstract
Objective To determine the effect of a pre-pregnancy lifestyle intervention on glucose tolerance in people at higher risk of gestational diabetes mellitus (GDM).
Design Randomised controlled trial.
Setting University hospital in Trondheim, Norway.
Participants 167 people with at least one risk factor for GDM who contemplated pregnancy.
Intervention The participants were randomly allocated (1:1) to a lifestyle intervention or a standard care control group. The intervention consisted of exercise training and time-restricted eating, started pre-pregnancy and continued throughout pregnancy. Exercise volume was set using a physical activity metric that translates heart rate into a score (Personal Activity Intelligence, PAI), with the goal of ≥ 100 weekly PAI-points. Time-restricted eating involved consuming all energy within ≤ 10 hours/day, ≥ 5 days per week.
Main outcome measures 2-hour plasma glucose level in an oral glucose tolerance test (OGTT) in gestational week 28. The primary analysis used an intention-to-treat principle.
Results From 02.10.2020 to 12.05.2023, we included 167 participants: 84 in intervention and 83 in control, out of whom 111 became pregnant (56 in intervention and 55 in control). One participant in the intervention group was excluded from the analysis because of pre-pregnancy diabetes. Pregnancy data from one participant in the control group were excluded from the analysis because of twin pregnancy. Time to pregnancy was 112 days (SD 105) in the intervention (INT) group and 83 days (SD 69) in the control (CON) group (p = .087). The intervention had no significant effect on 2-hour plasma glucose level in an OGTT in gestational week 28 (mean difference, 0.48 mmol/L, 95% confidence interval [CI], -0.05 to 1.01, p = .077). There was no evidence of between-group differences in other measures of glycaemic control before or during pregnancy. The intervention did not significantly influence GDM prevalence rates in gestational week 12 (INT 5.5%, CON 5.6%, p = 1.000) or gestational week 28 (INT 14.5%, CON 11.1%, p = .592). In gestational week 28, the intervention group had gained less weight (2.0 kg, 95% CI, -3.3 to -0.8, p = .002) and fat mass (-1.5 kg, 95% CI, -2.5 to -0.4, p = .008) than the control group. Participants could adhere to the ≤ 10-hour eating window and maintain ≥ 100 PAI per rolling week pre-pregnancy, but adherence to both intervention components decreased during pregnancy.
Conclusions A combination of time-restricted eating and exercise training started before and continued throughout pregnancy had no significant effect on glycaemic control in late pregnancy, but our findings suggest that the intervention lowered gestational weight and fat mass gain in people with increased risk of GDM.
Trial registration ClinicalTrials.gov NCT04585581
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04585581
Clinical Protocols
https://bmjopen.bmj.com/content/13/10/e073572.info
Funding Statement
The trial is funded by the Novo Nordisk Foundation (NNF19SA058975), The Liaison Committee for education, research, and innovation in Central Norway, and The Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU (FFU).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Committees for Medical and Health Research Ethics in Norway approved the study (REK 143756).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared first author
E-mail addresses: MAJS: md.a.j.sujan{at}ntnu.no, HMSS: hanna.s.skarstad{at}ntnu.no, GR: guro.rosvold{at}ntnu.no, SLF: stine.fougner{at}ntnu.no, TF: turid.follestad{at}ntnu.no, KÅS: pepe.salvesen{at}ntnu.no, TM: trine.moholdt{at}ntnu.no
Data availability statement
Data reported in this paper can be shared by the corresponding author upon request.
